Home >> Tag Archives: NeoGenomics

Tag Archives: NeoGenomics

NeoGenomics to acquire Genoptix

Oct. 26, 2018—NeoGenomics has entered into a definitive agreement to acquire Genoptix for $125 million in cash and 1 million shares of NeoGenomics common stock. “The acquisition of Genoptix enhances NeoGenomics’ leadership in the oncology test market, significantly expanding our coverage of oncology practices, increasing our customer reach, and leaving us better positioned for growth,” Douglas M. VanOort, NeoGenomics’ chairman ...

Read More »

Cell-free DNA tests, 2/16

February 2016—NeoGenomics has expanded its liquid biopsy testing menu to include two new tests, a NeoLab Solid Tumor Monitor and a NeoLab BTK Inhibitor Acquired Resistance test. Each of the tests uses cell-free DNA from peripheral blood plasma without the need for tissue biopsies.

Read More »

NeoGenomics acquires Clarient, 12/15

December 2015—NeoGenomics has reached an agreement to acquire Clarient and its wholly owned subsidiary Clarient Diagnostic Services. Clarient, a unit of GE Healthcare’s Life Sciences business, is based in Houston and in Aliso Viejo, Calif., and has approximately 415 employees. Clarient had 2014 revenue of $127 million.

Read More »
CAP TODAY
X